Advisors

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Dr Bahl is currently CSO at Carrick Therapeutics. He has 25 years of international Pharmaceutical experience leading collaborations in US, Japan, and Europe. His previous roles were with Eli Lilly (Vice President of External Innovation), AstraZeneca (Vice President Head of R&D New Opportunities) and Glaxo. Dr Bahl has delivered over 10 compounds into clinical development from his leadership of drug discovery projects in R&D.

Ash Bahl

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Oran is an innovator within the healthcare technology industry, with over 30 years of experience, dedicated to improving quality and access to healthcare. He has founded and successfully exited multiple startups. He was the business line leader for care delivery platforms within Alphabet and the CEO of Medicalis, a joint venture with Harvard Medical School (acquired by Siemens in 2017). He was the CEO of Stentor, the company that played a pivotal role in bringing radiology reading into the digital age. Upon Stentor’s acquisition, by Philips Medical Systems, Oran stayed on as CEO of Healthcare Informations & Patient Monitoring.

Oran Muduroglu

Life Sciences, AI & Software, Healthtech, Deep Tech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Michel Lussier is a serial entrepreneur in MedTech, BioTech and Digital Health sharing his time between Montreal and Brussels. After 15 foundational years at Medtronic, Michel served as CEO or C. Suite executive for a number of private and publicly listed companies such as InControl, Novoste, Volcano Corp. and others. Michel now dedicates his time to the coaching of young entrepreneurs and early stage companies. Michel currently serves on several companies’ boards, chairman of 3. Michel obtained a BSEE and M.ING. degree in Biomedical Engineering at the University of Montreal. He also holds an MBA from INSEAD.

Michel Lussier

Life Sciences, Healthtech, AI & Software

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Pete Hutton is an Angel investor, Advisor, and Chair for several startups and scale-ups in Cambridge, Edinburgh, London, and Oxford. His previous full-time role was as president of product groups at Arm, where he was responsible for all product development, marketing and licensing. This covered 3,500 staff, in more than 25 global locations, and working closely with a range of global Partners. In his three years in the role, revenue increased by around 50% (> $500m). Prior to that, Pete held senior positions within other Arm divisions, ran corporate engineering for Wolfson, was general manager for processors at ARC and a group director for Cadence. Pete understands long-term strategy, medium-term planning and the need to balance those with a focus on short-term execution. He is personally familiar with Software, Hardware and Technology Licensing.

Pete Hutton

Deep Tech, AI & Software

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Investment bank General Counsel & Chief Risk Officer with over 20 years experience across legal, risk, compliance and regulatory disciplines and corporate transactions including IPOs and M&A. Significant experience working with high growth companies about fundraisings (series C through IPO) and the development of new products, international expansion, growth, change and platform enhancing projects. Before working in investment banking, Michael was a corporate, capital markets and transactional lawyer at Magic Circle law firm Linklaters and leading US law firm Latham & Watkins.@

Michael Lee

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Helen Routh is a Boston based HealthTech board director and advisor with experience building & scaling new businesses & driving change in growth settings. Working across health systems, startups & public companies as Chair of Ultromics, a non-executive Director at Agfa and Health Innovation Manchester, and an advisor to Buoy Health and Nina Capital. As a senior executive at Philips, she worked in strategy, innovation & general management in multi-billion businesses and new ventures, focusing on data to improve outcomes. Helen also spends time to support women leaders and is on the advisory board of MedExec Women

Helen Routh

Healthtech, AI & Software

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Visionary MD/PhD and success-proven R&D executive and Board member. Significant track record in financing biopharmaceutical companies incl. successful public offerings (>700m US$ raised in private and public financing rounds) both as CxO and Board member/advisor (non-executive director) of such companies. Has been instrumental in numerous deals with large pharma/biotech with repeated deal values achieved in the > 1b USD range. Strong background in scientific/clinical/medical leadership roles within various environments. Successfully build and led international dynamic high-performance teams. Oversaw the transition of >20 new compounds/concepts from research/translational stage through first-in-man studies into later-stage clinical development. Has overseen and directed multiple successful BLA/MAA filings (including Herceptin and Blincyto).

Dr. Carsten Reinhardt

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Dr. Chapman is an executive business leader from startup to Fortune 50, company founder, equity investor and director. She currently serves as an independent director at Evidation Health and Natera, Inc. (Nasdaq: NTRA) and is a co-founder of Initiate Studios, a life sciences incubator. She has led the execution of more than 80 partnerships and investments across healthcare verticals including life sciences tools, therapeutics, diagnostics, medical devices, vaccines and digital health.

Rowan Chapman

Life Sciences, Healthtech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Khatereh has worked in the industry for 18 years. She currently leads the BD team in Europe and Middle East for MSD. Previously, she was a co-founder/CEO of reViral, leading a Series A of $21M. She played a significant role in the spin out/ company building of other biotechs eg Piramed, which was acquired by Roche. She has consulted for a number of EU/US companies in the oncology field. She obtained a PhD from King’s College London followed by a post-doctoral at the Ludwig Institute for Cancer Research working in cancer biology. She was awarded an MBA in 2008.

Khatereh Ahmadi

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

An accomplished global HR leader with over 20 years of experience, I’ve set and led the people agenda in four businesses, including Immunocore, Genomics Plc and Sophos. All of whom scaled up significantly in people and evolved from being founder-led and growing their global presence (Asia, Europe and the US). My HR experience covers the full HR remit from hiring to compensation, diversity to executive guidance, and everything in-between. On any piece of work – large or small – I strive to understand the business goals first and then provide the simplest, most pragmatic advice and hands-on support.

Ken Paul

Life Sciences, AI & Software, Healthtech, Deep Tech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Heidi Henson has served as the Chief Financial Officer of Pardes Biosciences Inc., a privately-held clinical-stage biopharmaceutical company, since January 2021. From April 2019 to July 2020, Ms. Henson served as Chief Financial Officer of Imbria Pharmaceuticals, Inc., a privately-held biotechnology company, and from November 2018 to April 2019 she served as Chief Financial Officer of Respivant Sciences, a privately-held clinical-stage biopharmaceutical company. From October 2014 to July 2018, Ms. Henson served as Chief Financial Officer of Kura Oncology, Inc., a public biopharmaceutical company. Ms. Henson also served as Chief Financial Officer of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, and its parent company Araxes Pharma LLC, from July 2012 to July 2018 and served as Secretary of Wellspring and Araxes from July 2012 to January 2015. From 2007 to March 2012, Ms. Henson served as the Vice President, Finance at Intellikine, Inc., a privately-held biopharmaceutical company, until its acquisition by Takeda Pharmaceutical Company Limited. Ms. Henson previously served as an independent financial consultant for several years assisting with various start-up activities for early stage companies, SEC reporting and Sarbanes-Oxley implementation and compliance. Ms. Henson began her career in auditing at PricewaterhouseCoopers LLP, a public accounting firm, where she served both public and private companies. Ms. Henson currently serves on the board of directors of PepGen, Inc. and Cend Therapeutics, Inc. She received a Bachelor’s of Accountancy from the University of San Diego and is a Certified Public Accountant (inactive) in the state of California.

Heidi Henson

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Kirsty is the Head of Investor Relations for Waymo, an autonomous driving company with a mission to make it safe and easy for people and things to get where they want to go. To date Waymo has raised $5.75bn from a world-class investor base including sovereign wealth funds, prominent growth tech investors and pension funds. Before this, Kirsty was the CEO of an OSI portfolio company spun out from the Oxford University Computer Sciences department, which was acquired by Waymo in 2019. She started her career at management consulting firm Oliver Wyman, before becoming an executive director for The AA.

Kirsty Lloyd-Jukes

AI & Software

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Independent biotech entrepreneur. Founder of several early-stage biotech companies active in the discovery and development of biologics such as therapeutic antibodies in the field of immune diseases and cancer. 10 years of experience as venture parter at a major VC firm.

Mark de Boer

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Sanjay is a physician-scientist with broad R&D expertise in diverse therapeutic areas, including Neuroscience, Rare Diseases, Autoimmunity, Pain, Fibrosis, Virology and Ophthalmology. He has held executive leadership positions in both big pharma (e.g., Roche, BMS, Eli Lilly) and small biotech with success in raising capital (including Series A, D, IPO rounds) and driving multiple industry partnerships. He has prosecuted drug development in over 50 diseases, including several approved medicines such as Cymbalta, Aimovig, Risdiplam and Emgality. He is a Neurology Faculty member at The Johns Hopkins Hospital and elected Fellow of the Royal College of Physicians, UK.

Sanjay Keswani

Life Sciences, Healthtech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Andrew started with an academic apprenticeship in UK M&A at Goldman Sachs, followed by a more worldly practical apprenticeship as a small business owner retailing electrical goods in London. Andrew has been CEO of FTSE 250 Telecom Plus plc for over a decade overseeing its growth and diversification from large start-ups to small corporate. I am excited by people, growth, consumer-facing businesses, and the challenge of the transition to net-zero.

Andrew Lindsay

Deep Tech, AI & Software

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Mark is currently Chief Executive Officer of DeepMatter Group plc. He is widely recognised in the UK and international life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team and prior to that as Managing Director at Tripos Discovery Research a pre-clinical CRO. Mark is currently a non-executive director at Ixico Plc, but has served as chairman and non-executive director on a number of high growth life science and technology companies, both public and private, in the past 10 years.

Mark Warne

Life Sciences, AI & Software, Healthtech, Deep Tech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

A clinical development executive with 30 years’ experience in the biopharmaceutical sector. Excelled in global leadership roles within clinical development, built high performing teams, successfully managing between the US and Europe. Significant haematology/oncology experience including immuno-oncology and cell & gene therapy in both large companies and biotech. Broad experience across the Development spectrum from candidate selection to first-in-human trials, regulatory approval, and commercialisation.

Jen Renwick

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Life science thought leader. Biopharmaceutical executive with broad bench to bedside global experience across public and private sectors

Annalisa Jenkins

Life Sciences, Deep Tech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

A senior Board level Executive, extensive knowledge of Drug Discovery and Development with over 30 years experience in biotech and pharmaceuticals including biologics and small molecules. Directly involved in taking chemicals and biologics through research, preclinical and manufacture to clinical proof of principle studies. A start up CEO and Biotech Founder with extensive experience as CSO and as CSO/Director of of established Biotech companies leading to Pharma acquisition with a practical in depth practical understanding of the drug discovery, preclinical and clinical development process and associated regulatory environment. Mick has a PhD from the University of Nottingham and has managed multiple clinical development programs and academic and Pharma collaborations. He has experience in the management, strategy and growth of early stage companies turning concepts into clinical candidates. He is also experienced in raising venture capital for life science companies

Michael Hunter

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

I am an ex-investment banker - having worked in the City for over 30 years advising companies on their strategies to raise capital and execute M&A plans both buying and selling. I specialied mostly in the healthcare and IT sectors and have worked with all sizes and stages of companies. I now do consultancy and non-executive director work and would relish being able to share my experience and knowledge with exciting young and growing companies.

Michael Meade

Life Sciences, Healthtech, AI & Software

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

John is a founder and investor interested in the intersection of biology and technology. He has over 10 years’ experience in drug development; spanning academia (University of Cambridge), industry (MedImmune) and start-ups. John was founder, and CEO of CCG.ai, a Y Combinator backed start-up brining AI to precision oncology, which exited to Dante Labs Inc in 2021. In addition to working with Oxford Science Enterprises, John is a Venture Partner at Kindred capital and an active angel investor. John holds a Masters in Pharmacology (1st Class; top UK graduate) from the University of Glasgow, a PhD in Functional Genomics from the University of Cambridge, and an MBA focussed on health economics. In 2018 John was honoured on the Forbes 30 Under 30 (Europe) list for his contributions to biotechnology and in 2020 he became the youngest Fellow of the Royal Society of Biology (FRSB).

John Cassidy

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Life science executive turned company co-founder / incubator, and non-executive director. Believes in a world where everyone has access to the healthcare one needs to thrive. Continuously juggling depth vs. breadth, US vs Europe, private vs. public funding, devices vs. therapeutics, cash-burn vs. cash-flow-positive, etc. - and enjoying to explore this together with the amazingly talented and driven humans one meets along this life-long journey.

Harald Stock

Healthtech, Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Big 4 trained senior international business and government executive with extensive global trade, investment and funding experience. Most recently Michael was HMG’s Chief Investment Officer based at the Department for International Trade. From multinational corporations to sovereign and institutional investors to startups Michael is passionate about helping organisations invest internationally, building and scaling their global presence. Michael is a global citizen having lived and worked in many markets including Brazil and China and with investors from across a range of sectors. Skilled at acting in an ambassadorial role, influencing and managing the complex interface between business and government including funding, national security, risk & reputation, commercial and policy outcomes. Used to operating creatively and with entrepreneurialism within a structured environment.

Michael Charlton

Life Sciences, AI & Software, Healthtech, Deep Tech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Alberto L. Sangiovanni-Vincentelli is the Edgar L. and Harold H. Buttner Chair at the EECS Department, UC Berkeley. He co-founded Cadence and Synopsys, the two leading EDA companies. He is on the Board of Directors of Cadence, KPIT, Expert.ai, Cy4Gate, Exein, and Chairman of the Board of Quantum Motion, Innatera, Phononic Vibes and Phoelex. He is a member of the advisory board of Walden International and Xseed, of the Scientific Advisory Board of the Italian Institute of Technology and the Chair of the International Advisory Board for the Milano Innovation District. He is a member of the Advisory Board of the Politecnico di Milano and honorary Professor at Politecnico di Torino. He was the President of the “Comitato Nazionale dei Garanti della Ricerca” and of the Strategy Committee of Fondo Strategico Italiano. He consulted for companies such as Intel, HP, Bell Labs, IBM, Lendlease, Samsung, UTC, Lutron, Camozzi Group, Kawasaki Steel, Fujitsu, Telecom Italia, Pirelli, GM, BMW, Mercedes, Magneti Marelli, ST Microelectronics, and ELT. He authored 1,120 papers, 19 books, and two patents. He is Fellow of the IEEE and ACM, and a member of the National Academy of Engineering. He earned the IEEE/RSE Maxwell Award “for groundbreaking contributions that have had an exceptional impact on the development of electronics and electrical engineering or related fields”, the Kaufmann Award, the EDAA lifetime Achievement Award, the IEEE/ACM R. Newton Impact Award, the University of California Distinguished Teaching Award, the IEEE TC-CPS Technical Achievement Award, the IEEE Leon Kirchmayer Graduate Teaching Award and the ISPD lifetime achievement award.

Alberto Sangiovanni Vincentelli

AI & Software, Deep Tech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Susan joined Oxford Science Enterprises Advisors in 2021. Susan is a financier with 25 years of capital markets and investment banking experience, including ten years at Citigroup and Salomon Smith Barney as Managing Director of Equity Capital Markets and most recently as Managing Director of Torreya, an investment bank solely focused on life sciences. She has extensive strategic, business development and financing experience for both listed and private companies. Susan is non-executive director and chair of the audit committee at MiNA Therapeutics, Evgen Pharma plc and Scancell Holdings plc, non-executive director at Exploristics, Advisor to Theolytics, an OxSciences portfolio company, and is on the Innovations Advisory Board at Chelsea & Westminster NHS Trust Hospital. Susan has a BSc in Economics from University College London and a MSc in Economics from London School of Economics.

Susan Clement Davies

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Ross is the founder and CEO of Ultromics, a University of Oxford spin-out technology company that has built an AI-based platform to automate analysis and predict patient outcomes in the field of cardiovascular imaging. Ross has a broad scientific background having undertaken 4 degrees in the clinical sciences. During the last 3 years, he has built Ultromics to be one of the most prominent companies in healthcare AI, leading the creation of EchoGo which has received FDA clearance and qualified for reimbursement. Ross has successfully raised multiple rounds of funding from investors including OSI, Blue Venture Fund, GV and Optum Ventures and was named on the 2019 Forbes 30 under 30 lists for science and healthcare.

Dr Ross Upton

AI & Software, Healthtech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Most recently, Olly was the Chairman and Managing Director of Accenture UKI with overall accountability for the client, people, and ESG performance of the $4b entity. Previously Olly was COO for two of Accenture’s global divisions. Olly continues to serve clients, providing c-level guidance on how ‘to deliver the promise of technology and human ingenuity’ – whether through overall operating model / organisation, customer experience, supply chains or business services. Olly is Chairman of Movement to Work, an advisory board member of the Productivity Leadership Group and Innovate UK. He sits on the UK's Digital Economy Council and is a member of the Made Smarter Commission. Before Accenture, Olly worked in Operational Research for Conoco and as an Engineer for British Aerospace. Olly holds a first-class honours degree in Engineering from Churchill College, Cambridge.

Olly Benzecry, CBE

AI & Software, Deep Tech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

I have over 20 years’ experience at Dyson, with direct accountability for the development of early technology ideas through to successful manufacturing, commercialisation and launch of consumer durable products. Working in a high-growth environment with a start-up mentality, I successfully diversified the company portfolio into Health and Beauty products, discovering and translating unmet consumer needs into specifications and product solutions. “Hardware is hard”, but also an extremely enjoyable challenge, and I’m now looking to help OSI entrepreneurs develop ground breaking ideas into products that will positively and purposefully impact peoples’ lives.

Paul Dawson

Life Sciences, Healthtech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Peter is a North American commercialization expert with over 30 years of experience building technology based organizations. Originally a bio-engineer at the Radcliffe in Oxford, segment experience spans healthcare, semiconductors, software and systems. Functional experience spans executive, engineering, sales, marketing, operations, strategy consulting and IP commercialization. Roles have included Principal at Regis McKenna in California, Health Sector lead at Intel, Senior Heath IT and Tech Advisor at MaRS Discovery District (N. America’s largest innovation hub), acting vice president of Vielight in Toronto. Peter also lead PeoplePC in Europe from 0-$35M and is a director at Inflexion Point Strategy in California.

Peter Adams

Healthtech, Life Sciences, Deep Tech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Mark Stevenson is Executive Vice President and Chief Operating Oﬀicer of Thermo Fisher Scientific, (NYSE: TMO) a $200B market cap, Fortune 100 healthcare company, leading scaled technology business groups globally. Chief Operating Officer of Thermo Fisher Scientific, a $200B market cap, Fortune 100 healthcare company, leading scaled technology business groups globally. Experienced in execution of growth strategies, transformations, M&A and integrations, as well as public and private investors. 30+ years experience in life sciences and healthcare. Board member of the Personalized Medicine Coalition.

Mark Stevenson

Life Sciences, Healthtech, AI & Software

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

During a 21year career in the Pharmaceutical Industry Nel has gained wide experience in Global Drug Discovery, Development, and Commercialisation, in the areas of Immunology, Oncology and Anti-Infectives. As Global Product Vice President in AstraZeneca, she led the Development, Submission and Approval of ZaviceftaTM. She went on to design, build and lead the Antibiotics Development organisation as part of a semi-autonomous Antibiotics Business Unit within AstraZeneca. Until the divestment of the products to Pfizer, this development organisation supported a portfolio of four antibiotics in various stage of development and commercialisation. Prior to focussing an anti-infectives Nel led cross functional Global Product Team for IRESSATM responsible for the 1st launch of IRESSA in Europe in 1st line for EGFR mutation positive patients, and FaslodexTM where she oversaw the 500mg world-wide label extensions. Since 2018 Nel have been helping Biotech, Corporate and non-for-profit organisations with strategic planning, implementation and execution of plans, and fundraising. Moreover, through her work with clients she has developed a broad knowledge base around the benefits digital technology can bring to R&D and patients across Therapy Areas. Nel has a BSc Hons and a PhD in Medical Biochemistry from Birmingham University (UK), and is currently Chair of the Board for CHAIN Biotechnology, non-executive director for PhagoMed, and a member of pre- and post-award advisory boards at CARB-X.

Nel Moore

Life Sciences, Healthtech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

I have held a number of senior roles at De Beers and within the jewellery industry , in the latter years developing new businesses and launching into the industry. I’m entrepreneurial by spirit and enjoy start up environments. I started my career in marketing and brand management with GSK and then joined the beauty / personal care industry for a decade working with Revlon , P&G , and Unilever. During this time I developed new brands and focussed the majority of my time on marketing , business development and business planning. I spent 8 years abroad with Unilever initially in NYC for 5 years as International Marketing Director and then in Geneva as VP international Markets reporting directly to the CEO. I decided to return to the U.K. and joined De Beers in 2001. Initially I established a new Key Account management team to look after their global client base . In 2004 I became Head of the International Marketing Group and then in 2008 Head of Operations for De Beers downstream business with a £200m budget and 500 + employees. In 2011 i was appointed SVP for De Beers Brands and from 2013-20 I launched a number of new businesses such as grading , synthetic detection, lab grown diamonds , an educational institution, and continues to head up operations for the brands. I retired from De Beers in 2020 and have a number of current roles. NED for Opsydia, CEO for Diamond Ancestry ( blockchain) , CEO for Diamonds4crypto ( trading ) , EVP for the World Jewellery Confederation (cibjo), Chairman for Pina Vida ( IT development co ) .

Jonathan Kendall

AI & Software

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Emma is a former CEO & business leader with a passion for building great teams and bringing innovations to market to address the worlds big challenges. Her particular interests are in supporting the Energy Transition in emerging markets and finding ways to accelerate the impact of healthcare innovations to improve patient outcomes. She has 25+ years experience in leading businesses in the Energy and Water sector around the world and has served on the Boards of plc, privately owned and not for profit organizations. She holds a DPhil in surface chemistry from Balliol College and an MBA from Manchester Business School.

Emma FitzGerald

Deep Tech, Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Vishal has experience in investment at the intersection of life sciences and engineering. He is an investor at Draper Esprit, where he has led investments in some of Europe’s leading digital healthcare companies, including Clue, PushDR, Lifesum and Evonetix. He is also a Director at Horizon Discovery and Sensyne Health. Vishal is Chairman of the Digital Health Forum and serves on Innovate UK’s Major Award committee. Vishal has previously worked at Atlas Venture, The Wellcome Trust and Radiant Capital. He trained in Medicine at the University of Oxford and received his postgraduate medical training at Imperial College London. He is a Rhodes scholar.

Dr. Vishal Gulati

Healthtech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Isabel is one of just a handful of female General Partners in the UK in her role as Partner at Luminous Ventures, an early-stage deep tech fund focused on human health (healthcare, life sciences, agriculture, food and wellness). Her portfolio at Luminous Ventures includes Synthace, Mahana, Phenomic, Temporall, Hadean, Optellum, Ellipsis, Vital Health, Huma and OxfordVR. Before venture capital, Isabel founded two corporate communications firms focused on the venture ecosystem (two exits), co-founded two software start-ups (one exit) and was an active angel investor in the UK and US.

Isabel Fox

AI & Software, Healthtech

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Jon has been an investor in life science companies since 1998. He is Founder of Rosetta Capital, a leading international secondary venture firm, focused on life sciences. Rosetta's investments include Catalyst Biosciences, Forward Pharma, Glycomimetics, Novimmune, Paratek, Polyphor and Zealand Pharmaceuticals. Rosetta's notable exits include Ambit Biosciences (acquired by Daiichi Sankyo for up to $410 million), Cytochroma (acquired by Opko for up to $290 million), Enobia Pharmaceuticals (acquired by Alexion for up to $1.08 billion) and GeminX Pharmaceuticals (acquired by Cephalon for up to $525 million). Jon's current board seats include Aprea AB, Clanotech AB, Procertus BioPharma Inc. and Novimmune. He is a Former Director of Seroba Kernel Life Sciences, Axelar AB, Covagen AG (acquired by Janssen affiliate Cilag) and Opsona Therapeutics.

Jonathan Hepple

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Chris is a seasoned biotech entrepreneur with over has 35 years’ experience in the biotechnology industry. Chris has considerable expertise in leading and growing early stage companies and their transition to mid-stage clinical development organisations. He has extensive international transactional experience in both listed and private companies including fund raising, licensing and M&A activity. Chris was formerly a Partner at Syncona, a FTSE250 company, where he was also founding CEO of Achilles Therapeutics. Prior to that he was CEO of Argenta Discovery (sold to Galapagos) and Pulmagen Therapeutics. Chris has a PhD from the University of Manchester (UMIST) and carried out post-doctoral research at the Massachusetts Institute of Technology (MIT).

Chris Ashton

Life Sciences

Thanks for your message. You will receive a reply shortly. In the meanwhile we will contact the advisor.

Best regards,

OxSciences team

Peter has extensive experience in growing successful international pharmaceutical and healthcare businesses. Peter was Founder and CEO of Clinigen Group, the FTSE AIM global pharmaceutical and services company. He is currently the Chairman of Benchmark Holdings plc, Enigma Holdings and Mitre Group. He was previously chairman of Ergomed plc, CEO of Penn Pharmaceutical Services and the Executive Vice President of a number of pharmaceutical companies. He co-created Unilabs Clinical Trials International in 1997, which was successfully sold to Icon in 2000. He holds an Executive MBA in Business Administration and Management from the Kellogg School of Management.

Peter George

Life Sciences

Reach out to Ash Bahl

Ash Bahl

Reach out to Oran Muduroglu

Oran Muduroglu

Reach out to Michel Lussier

Michel Lussier

Reach out to Pete Hutton

Pete Hutton

Reach out to Michael Lee

Michael Lee

Reach out to Helen Routh

Helen Routh

Reach out to Dr. Carsten Reinhardt

Dr. Carsten Reinhardt

Reach out to Rowan Chapman

Rowan Chapman

Reach out to Khatereh Ahmadi

Khatereh Ahmadi

Reach out to Ken Paul

Ken Paul

Reach out to Heidi Henson

Heidi Henson

Reach out to Kirsty Lloyd-Jukes

Kirsty Lloyd-Jukes

Reach out to Mark de Boer

Mark de Boer

Reach out to Sanjay Keswani

Sanjay Keswani

Reach out to Andrew Lindsay

Andrew Lindsay

Reach out to Mark Warne

Mark Warne

Reach out to Jen Renwick

Jen Renwick

Reach out to Annalisa Jenkins

Annalisa Jenkins

Reach out to Michael Hunter

Michael Hunter

Reach out to Michael Meade

Michael Meade

Reach out to John Cassidy

John Cassidy

Reach out to Harald Stock

Harald Stock

Reach out to Michael Charlton

Michael Charlton

Reach out to Alberto Sangiovanni Vincentelli

Alberto Sangiovanni Vincentelli

Reach out to Susan Clement Davies

Susan Clement Davies

Reach out to Dr Ross Upton

Dr Ross Upton

Reach out to Olly Benzecry, CBE

Olly Benzecry, CBE

Reach out to Paul Dawson

Paul Dawson

Reach out to Peter Adams

Peter Adams

Reach out to Mark Stevenson

Mark Stevenson

Reach out to Nel Moore

Nel Moore

Reach out to Jonathan Kendall

Jonathan Kendall

Reach out to Emma FitzGerald

Emma FitzGerald

Reach out to Dr. Vishal Gulati

Dr. Vishal Gulati

Reach out to Isabel Fox

Isabel Fox

Reach out to Jonathan Hepple

Jonathan Hepple

Reach out to Chris Ashton

Chris Ashton

Reach out to Peter George

Peter George

Sign up to our quarterly newsletter.

Connect